Late-Breaking from ASH22 – Let’s Keep the Standard Consolidation Therapy with HDC-ASCT for PCNSL Patients

The first results from the MATRix/IELSG43 trial indicate that standard consolidation therapy with high-dose chemotherapy and autologous stem cell transplantation results in significantly better outcomes when compared to non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.